Relationships of adrenoceptor polymorphisms with obesity

Journal of Obesity

Volumn 2011, Issue , 2011, Pages

  Masuo, Kazuko ^a,b   Lambert, Gavin W ^b  

^a Nucleus Network Ltd   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896985104     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2011/609485     Document Type: Article

References (115)

1. Mokdad A. H., Bowman B. A., Ford E. S., Vinicor F., Marks J. S., Koplan J. P., The continuing epidemics of obesity and diabetes in the United States. The Journal of the American Medical Association 2001 286 10 1195 1200 2-s2.0-0035850402 (Pubitemid 33015548)
2. Heidemann C., Boeing H., Pischon T., Nöthlings U., Joost H. G., Schulze M. B., Association of a diabetes risk score with risk of myocardial infarction, stroke, specific types of cancer, and mortality: a prospective study in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort. European Journal of Epidemiology 2009 24 6 281 288 2-s2.0-67349134980 10.1007/s10654-009-9338-7
3. Flegal K. M., Graubard B. I., Williamson D. F., Gail M. H., Cause-specific excess deaths associated with underweight, overweight, and obesity. The Journal of the American Medical Association 2007 298 17 2028 2037 2-s2.0-35848935201 10.1001/jama.298.17.2028 (Pubitemid 350074800)
4. Lambert E., Sari C. I., Dawood T., Nguyen J., McGrane M., Eikelis N., Chopra R., Wong C., Chatzivlastou K., Head G., Straznicky N., Esler M., Schlaich M., Lambert G., Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension 2010 56 3 351 358 2-s2.0-77954407835 10.1161/HYPERTENSIONAHA.110.155663
5. Ramsey F., Ussery-Hall A., Garcia D., McDonald G., Easton A., Kambon M., Balluz L., Garvin W., Vigeant J., Prevalence of selected risk behaviors and chronic diseases: behavioral Risk Factor Surveillance System (BRFSS), 39 steps communities, United States, 2005. Morbidity and Mortality Weekly Report. Surveillance Summaries/CDC 2008 57 11 1 20
6. Ogden C. L., Fryar C. D., Carroll M. D., Flegal K. M., Mean body weight, height, and body mass index, United States 1960-2002. Advance Data 2004 347 1 17
7. Mokdad A. H., Serdula M. K., Dietz W. H., Bowman B. A., Marks J. S., Koplan J. P., The spread of the obesity epidemic in the United States, 1991-1998. The Journal of the American Medical Association 1999 282 16 1519 1522 2-s2.0-0032697493 10.1001/jama.282.16.1519 (Pubitemid 29504044)
8. Lambert G. W., gavin.lambert@bakeridi.edu.au Straznicky N. E., Lambert E. A., Dixon J. B., Schlaich M. P., Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications. Pharmacology and Therapeutics 2010 126 2 159 172 10.1016/j.pharmthera.2010.02. 002
9. Preis S. R., Hwang S. J., Coady S., Pencina M. J., D'Agostino R. B., Savage P. J., Levy D., Fox C. S., Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the framingham heart study, 1950 to 2005. Circulation 2009 119 13 1728 1735 2-s2.0-65349085059 10.1161/CIRCULATIONAHA.108.829176
10. Straznicky N. E., Lambert G. W., Masuo K., Dawood T., Eikelis N., Nestel P. J., McGrane M. T., Mariani J. A., Socratous F., Chopra R., Esler M. D., Schlaich M. P., Lambert E. A., Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. American Journal of Clinical Nutrition 2009 89 1 27 36 2-s2.0-58149379409 10.3945/ajcn.2008.26299
11. Masuo K., Mikami H., Ogihara T., Tuck M. L., Differences in insulin and sympathetic responses to glucose ingestion due to family history of hypertension. American Journal of Hypertension 1996 9 8 739 745 2-s2.0-0029740993 10.1016/0895-7061(96)00204-X (Pubitemid 26271218)
12. Spraul M., Ravussin E., Fontvieille A. M., Rising R., Larson D. E., Anderson E. A., Reduced sympathetic nervous activity. A potential mechanism predisposing to body weight gain. Journal of Clinical Investigation 1993 92 4 1730 1735 2-s2.0-0027360269 (Pubitemid 23304536)
13. Cypess A. M., Lehman S., Williams G., Tal I., Rodman D., Goldfine A. B., Kuo F. C., Palmer E. L., Tseng Y. H., Doria A., Kolodny G. M., Kahn C. R., Identification and importance of brown adipose tissue in adult humans. The New England Journal of Medicine 2009 360 15 1509 1517 2-s2.0-64349105205 10.1056/NEJMoa0810780
14. Timmons J. A., Pedersen B. K., The importance of brown adipose tissue. The New England Journal of Medicine 2009 361 4 415 416 2-s2.0-67651166870 10.1056/NEJMc091009
15. Sacks H. S., The importance of brown adipose tissue. The New England Journal of Medicine 2009 361 4 418 2-s2.0-67651176110
16. Iwashita S., Tanida M., Terui N., Ootsuka Y., Shu M., Kang D., Suzuki M., Direct measurement of renal sympathetic nervous activity in high-fat diet-related hypertensive rats. Life Sciences 2002 71 5 537 546 2-s2.0-0037150766 10.1016/S0024-3205(02)01707-1 (Pubitemid 34607645)
17. Monroe M. B., Seals D. R., Shapiro L. F., Bell C., Johnson D., Parker-Jones P., Direct evidence for tonic sympathetic support of resting metabolic rate in healthy adult humans. American Journal of Physiology 2001 280 5 E740 E744 2-s2.0-0035010368
18. Blaak E. E., van Baak M. A., Kempen K. P. G., Saris W. H. M., Role of α-and β -adrenoceptors in sympathetically mediated thermogenesis. American Journal of Physiology 1993 264 1, part 1 E11 E17 2-s2.0-0027388998 (Pubitemid 23054681)
19. Hagström-Toft E., Enoksson S., Moberg E., Bolinder J., Arner P., β -adrenergic regulation of lipolysis and blood flow in human skeletal muscle in vivo. American Journal of Physiology 1998 275 6 E909 E916 2-s2.0-0032445831
20. Enoksson S., Talbot M., Rife F., Tamborlane W. V., Sherwin R. S., Caprio S., Impaired in vivo stimulation of lipolysis in adipose tissue by selective β 2-adrenergic agonist in obese adolescent girls. Diabetes 2000 49 12 2149 2153 2-s2.0-0033645792
21. Masuo K., Mikami H., Ogihara T., Tuck M. L., Familial hypertension, insulin, sympathetic activity, and blood pressure elevation. Hypertension 1998 32 1 96 100 2-s2.0-0031925914 (Pubitemid 28324131)
22. Masuo K., Mikami H., Ogihara T., Tuck M. L., Familial obesity, sympathetic activation and blood pressure level. Blood Pressure 2001 10 4 199 204 2-s2.0-0035215321 10.1080/08037050152669701 (Pubitemid 33149899)
23. Cui J., Hopper J. L., Harrap S. B., Genes and family environment explain correlations between blood pressure and body mass index. Hypertension 2002 40 1 7 12 2-s2.0-0036314870 10.1161/01.HYP.0000022693.11752.E9 (Pubitemid 34755971)
24. Masuo K., kmasuo@baker.edu.au Katsuya T., Fu Y., Rakugi H., Ogihara T., Tuck M. L., β 2- and β 3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation 2005 111 25 3429 3434 10.1161/CIRCULATIONAHA.104.519652 (Pubitemid 40923396)
25. Pereira A. C., Floriano M. S., Mota G. F. A., Cunha R. S., Herkenhoff F. L., Mill J. G., Krieger J. E., β 2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population. Hypertension 2003 42 4 685 692 2-s2.0-0141928183 10.1161/01.HYP.0000085648. 65419.17 (Pubitemid 37237310)
26. Masuo K., Katsuya T., Kawaguchi H., Fu Y., Rakugi H., Ogihara T., Tuck M. L., Rebound weight gain as associated with high plasma norepinephrine levels that are mediated through polymorphisms in the β 2-adrenoceptor. American Journal of Hypertension 2005 18 11 1508 1516 2-s2.0-27644514699 10.1016/j.amjhyper.2005.05.006 (Pubitemid 41566684)
27. Masuo K., Katsuya T., Fu Y., Rakugi H., Ogihara T., Tuck M. L., β 2-adrenoceptor polymorphisms relate to insulin resistance and sympathetic overactivity as early markers of metabolic disease in nonobese, normotensive individuals. American Journal of Hypertension 2005 18 7 1009 1014 2-s2.0-22844435290 10.1016/j.amjhyper.2005.01.006 (Pubitemid 41040275)
28. Masuo K., Katsuya T., Kawaguchi H., Fu Y., Rakugi H., Ogihara T., Tuck M. L., β 2-adrenoceptor polymorphisms relate to obesity through blunted leptin-mediated sympathetic activation. American Journal of Hypertension 2006 19 10 1084 1091 2-s2.0-33749353201 10.1016/j.amjhyper.2006.02.015 (Pubitemid 44488664)
29. Kawaguchi H., Masuo K., kmasuo@baker.edu.au Katsuya T., Sugimoto K., Rakugi H., Ogihara T., Tuck M. L., β 2- and β 3-adrenoceptor polymorphisms relate to subsequent weight gain and blood pressure elevation in obese normotensive individuals. Hypertension Research 2006 29 12 951 959 10.1291/hypres.29.951 (Pubitemid 46206581)
30. Maxwell T. J., Ameyaw M. M., Pritchard S., Thornton N., Folayan G., Githang'a J., Indalo A., Tariq M., Mobarek A., Evans D. A., Ofori-Adjei D., Templeton A. R., McLeod H. L., Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. International Journal of Molecular Medicine 2005 16 4 573 580 2-s2.0-33644682845
31. Straznicky N. E., Eikelis N., Lambert E. A., Esler M. D., Mediators of sympathetic activation in metabolic syndrome obesity. Current Hypertension Reports 2008 10 6 440 447 2-s2.0-58949099728 10.1007/s11906-008-0083-1
32. González Sánchez J. L., Proenza A. M., Martínez Larrad M. T., Ramis J. M., Fernández Pérez C., Palou A., Serrano Ríos M., uinvest7@hcsc.insalud.es The glutamine 27 glutamic acid polymorphism of the β 2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain. Clinical Endocrinology 2003 59 4 476 481 10.1046/j.1365-2265.2003.01871.x (Pubitemid 37188178)
33. Straznicky N. E., nora.straznicky@baker.edu.au Lambert E. A., Lambert G. W., Masuo K., Esler M. D., Nestel P. J., Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. Journal of Clinical Endocrinology & Metabolism 2005 90 11 5998 6005 10.1210/jc.2005-0961 (Pubitemid 41606517)
34. Landsberg L., Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). Journal of Hypertension 2001 19 3 523 528 2-s2.0-0035066361 10.1097/00004872-200103001-00001 (Pubitemid 32280942)
35. Anderson E. A., Hoffman R. P., Balon T. W., Sinkey C. A., Mark A. L., Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. Journal of Clinical Investigation 1991 87 6 2246 2252 2-s2.0-0025995364
36. Ferrannini E., Physiological and metabolic consequences of obesity. Metabolism 1995 44 9, supplement 3 15 17 2-s2.0-0029375387
37. Montani J.-P., Antic V., Yang Z., Dulloo A., Pathways from obesity to hypertension: from the perspective of a vicious triangle. International Journal of Obesity 2002 26 supplement 2 S28 S38 (Pubitemid 35034485)
38. Gentile C. L., Orr J. S., Davy B. M., Davy K. P., Modest weight gain is associated with sympathetic neural activation in nonobese humans. American Journal of Physiology 2007 292 5 R1834 R1838 2-s2.0-34248178259 10.1152/ajpregu.00876.2006 (Pubitemid 46708538)
39. Barnes M. J., Lapanowski K., Conley A., Rafols J. A., Jen K. L. C., Dunbar J. C., High fat feeding is associated with increased blood pressure, sympathetic nerve activity and hypothalamic mu opioid receptors. Brain Research Bulletin 2003 61 5 511 519 2-s2.0-0141566812 10.1016/S0361-9230(03)00188-6 (Pubitemid 37117198)
40. Masuo K., Mikami H., Ogihara T., Tuck M. L., Weight reduction and pharmacologic treatment in obese hypertensives. American Journal of Hypertension 2001 14 6, part 1 530 538 2-s2.0-0034992647 10.1016/S0895-7061(00)01279-6 (Pubitemid 32506726)
41. Andersson B., Elam M., Wallin B. G., Bjorntorp P., Andersson O. K., Effect of energy-restricted diet on sympathetic muscle nerve activity in obese women. Hypertension 1991 18 6 783 789 2-s2.0-0026410492
42. Straznicky N. E., Lambert E. A., Lambert G. W., Masuo K., Esler M. D., Nestel P. J., Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. Journal of Clinical Endocrinology & Metabolism 2005 90 11 5998 6005 2-s2.0-27744591354 10.1210/jc.2005-0961 (Pubitemid 41606517)
43. Masuo K., Mikami H., Ogihara T., Tuck M. L., Differences in mechanisms between weight loss-sensitive and -resistant blood pressure reduction in obese subjects. Hypertension Research 2001 24 4 371 376 2-s2.0-0034844473 10.1291/hypres.24.371 (Pubitemid 32792437)
44. Tuck M. L., Sowers J. R., Dornfeld L., Reductions in plasma catecholamines and blood pressure during weight loss in obese subjects. Acta Endocrinologica 1983 102 2 252 257 2-s2.0-0020659009 (Pubitemid 13170148)
45. Grassi G., Seravalle G., Colombo M., Bolla G., Cattaneo B. M., Cavagnini F., Mancia G., Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998 97 20 2037 2042 2-s2.0-0032568488 (Pubitemid 28243666)
46. Landsberg L., Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. The Quarterly Journal of Medicine 1986 61 236 1081 1090 2-s2.0-0022856921 (Pubitemid 17230168)
47. Landsberg L., Young J. B., Diet and the sympathetic nervous system: relationship to hypertension. International Journal of Obesity 1981 5 supplement 1 79 91 2-s2.0-0019796462 (Pubitemid 11090056)
48. Landsberg L., Krieger D. R., Obesity, metabolism, and the sympathetic nervous system. American Journal of Hypertension 1989 2 3 125S 132S 2-s2.0-0024523219 (Pubitemid 19082352)
49. Julius S., Valentini M., Palatini P., Overweight and hypertension: a 2-way street? Hypertension 2000 35 3 807 813 2-s2.0-0034060897 (Pubitemid 30165330)
50. O'Dea K., Esler M., Leonard P., Noradrenaline turnover during under- and over-eating in normal weight subjects. Metabolism 1982 31 9 896 899 (Pubitemid 12049442)
51. Masuo K., Kawaguchi H., Mikami H., Ogihara T., Tuck M. L., Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003 42 4 474 480 2-s2.0-0141962657 10.1161/01.HYP.0000091371.53502.D3 (Pubitemid 37237341)
52. Masuo K., Mikami H., Ogihara T., Tuck M. L., Weight gain-induced blood pressure elevation. Hypertension 2000 35 5 1135 1140 2-s2.0-0034110536 (Pubitemid 30327270)
53. Valentini M., Julius S., Palatini P., Brook R. D., Bard R. L., Bisognano J. D., Kaciroti N., Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension. Journal of Hypertension 2004 22 10 1999 2006 2-s2.0-5044231782 10.1097/00004872-200410000- 00024 (Pubitemid 39336684)
54. Yang Y. T., McElligott M. A., Multiple actions of β -adrenergic agonists on skeletal muscle and adipose tissue. Biochemical Journal 1989 261 1 1 10 2-s2.0-0024333198 (Pubitemid 19174752)
55. Large V., Hellstrom L., Reynisdottir S., Lonnqvist F., Eriksson P., Lannfelt L., Arner P., Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. Journal of Clinical Investigation 1997 100 12 3005 3013 (Pubitemid 28022837)
56. Ukkola O., Tremblay A., Bouchard C., Beta-2 adrenergic receptor variants are associated with subcutaneous fat accumulation in response to long-term overfeeding. International Journal of Obesity 2001 25 11 1604 1608 10.1038/sj.ijo.0801810 (Pubitemid 33052067)
57. Enoksson S., Hagström-Toft E., Nordahl J., Hultenby K., Pettersson N., Isaksson B., Permert J., Wibom R., Holm C., Bolinder J., Arner P., Marked reutilization of free fatty acids during activated lipolysis in human skeletal muscle. Journal of Clinical Endocrinology & Metabolism 2005 90 2 1189 1195 2-s2.0-20044366004 10.1210/jc.2004-1079 (Pubitemid 40279253)
58. Echwald S. M., Sørensen T. I. A., Tybjærg-Hansen A., Andersen T., Pedersen O., Gln27Glu variant of the human β 2-adrenoreceptor gene is not associated with early-onset obesity in Danish men. Diabetes 1998 47 10 1657 1658 2-s2.0-0031685380 10.2337/diabetes.47.10.1657 (Pubitemid 28445358)
59. Hellström L., Large V., Reynisdottir S., Wahrenberg H., Arner P., The different effects of a Gln27Glu β 2-adrenoceptor gene polymorphism on obesity in males and in females. Journal of Internal Medicine 1999 245 3 253 259 2-s2.0-0032998134 10.1046/j.1365-2796.1999.0437e.x (Pubitemid 29132968)
60. 1-adrenoceptor gene (Gly389Arg ADRB1) in Caucasian women. International Journal of Obesity 2002 26 5 633 639 10.1038/sj.ijo.0801971 (Pubitemid 34499282)
61. Tafel J., Branscheid I., Skwarna B., Schlimme M., Morcos M., Algenstaedt P., Hinney A., Hebebrand J., Nawroth P., Hamann A., andreas-hamann@med.uni- heidelberg.de Variants in the human β 1-, β 2- and β 3-adrenergic receptor genes are not associated with morbid obesity in children and adolescents. Diabetes, Obesity & Metabolism 2004 6 6 452 455 10.1111/j.1462-8902.2004.00366.x (Pubitemid 39409796)
62. Linné Y., Dahlman I., Hoffstedt J., β 1-adrenoceptor gene polymorphism predicts long-term changes in body weight. International Journal of Obesity 2005 29 5 458 462 2-s2.0-17844374080 10.1038/sj.ijo.0802892 (Pubitemid 40592986)
63. Gjesing A. P., apri@steno.dk Andersen G., Albrechtsen A., Studies of associations between the Arg389Gly polymorphism of the β 1-adrenergic receptor gene (ADRB1) and hypertension and obesity in 7677 Danish white subjects. Diabetic Medicine 2007 24 4 392 397 10.1111/j.1464-5491.2006.02031.x (Pubitemid 46452390)
64. Nonen S., Yamamoto I., Liu J., Maeda M., Motomura T., Igarashi T., Fujio Y., Azuma J., Adrenergic β 1 receptor polymorphism (Ser49gly) is associated with obesity in type II diabetic patients. Biological & Pharmaceutical Bulletin 2008 31 2 295 298 2-s2.0-38849209778 10.1248/bpb.31.295 (Pubitemid 351198410)
65. Rasmussen M., mads.rasmussen@dadlnet.dk Belza A., Almdal T., Change in β 1-adrenergic receptor protein concentration in adipose tissue correlates with diet-induced weight loss. Clinical Science 2005 108 4 323 329 10.1042/CS20040238 (Pubitemid 40516995)
66. Ryden M., Hoffstedt J., Eriksson P., Bringman S., Arner P., The Arg389Gly β 1-adrenergic receptor gene polymorphism and human fat cell lipolysis. International Journal of Obesity 2001 25 11 1599 1603 10.1038/sj.ijo.0801815 (Pubitemid 33052066)
67. 1-adrenergic receptor gene and hypertension. Circulation 2001 104 2 187 190 2-s2.0-0035838467 (Pubitemid 32655836)
68. Humma L. M., Puckett B. J., Richardson H. E., Terra S. G., Andrisin T. E., Lejeune B. L., Wallace M. R., Lewis J. F., McNamara D. M., Picoult-Newberg L., Pepine C. J., Johnson J. A., Effects of beta-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. American Journal of Cardiology 2001 88 9 1034 1037 2-s2.0-0035497742 10.1016/S0002-9149(01)01986-5 (Pubitemid 33042620)
69. Kortner B., Wolf A., Wendt D., Beisiegel U., Evans D., evans@uke.uni-hamburg.de Lack of association between a human β -2 adrenoceptor gene polymorphism (gln27glu) and morbid obesity. International Journal of Obesity 1999 23 10 1099 1100 (Pubitemid 29476214)
70. Stob N. R., Seals D. R., Jensen J., van Baak M. A., Steig A. J., Lindstrom R. C., Bikman B. T., Bell C., cbell@cahs.colostate.edu Increased thermogenic responsiveness to intravenous β -adrenergic stimulation in habitually exercising humans is not related to skeletal muscle β 2-adrenergic receptor density. Experimental Physiology 2007 92 5 823 830 10.1113/expphysiol.2007.038174 (Pubitemid 47283907)
71. Meirhaeghe A., Helbecque N., Cottel D., Amouyel P., Philippe. Amouvel@pasteur-lille.fr Impact of polymorphisms of the human β 2-adrenoceptor gene on obesity in a French population. International Journal of Obesity 2000 24 3 382 387 (Pubitemid 30137732)
72. Bengtsson K., Orho-Melander M., Melander O., Lindblad U., Ranstam J., Råstam L., Groop L., β 2-adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes. Hypertension 2001 37 5 1303 1308 2-s2.0-0035717657 (Pubitemid 34163586)
73. Jiao H., Dahlman I., Eriksson P., Kere J., Arner P., A common β 2-adrenoceptor gene haplotype protects against obesity in Swedish women. Obesity Research 2005 13 10 1645 1650 2-s2.0-33644810884
74. Petrone A., Zavarella S., Iacobellis G., Zampetti S., Vania A., Di Pietro S., Galgani A., Leonetti F., Di Mario U., Buzzetti R., Association of β 2 adrenergic receptor polymorphisms and related haplotypes with triglyceride and LDL-cholesterol levels. European Journal of Human Genetics 2006 14 1 94 100 2-s2.0-29644442452 10.1038/sj.ejhg.5201521 (Pubitemid 43019089)
75. Gjesing A. P., Sparsø T., Borch-Johnsen K., Jørgensen T., Pedersen O., Hansen T., Olsen N. V., No consistent effect of ADRB2 haplotypes on obesity, hypertension and quantitative traits of body fatness and blood pressure among 6,514 adult danes. PLoS One 2009 4 9 2-s2.0-70349675425 10.1371/journal.pone.0007206 e7206
76. Eriksson P., Dahlman I., Ryden M., Hoffstedt J., Arner P., peter.arner@medhs.ki.se Relationship between β -2 adrenoceptor gene haplotypes and adipocyte lipolysis in women. International Journal of Obesity 2004 28 2 185 190 (Pubitemid 38223498)
77. Green S. A., Turki J., Innis M., Liggett S. B., Amino-terminal polymorphisms of the human β 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994 33 32 9414 9419 2-s2.0-0028068550 (Pubitemid 24272896)
78. Dishy V., Sofowora G. G., Xie H.-G., Kim R. B., Byrne D. W., Michael Stein C., Wood A. J. J., The effect of common polymorphisms of the β 2-adrenergic receptor on agonist-mediated vascular desensitization. The New England Journal of Medicine 2001 345 14 1030 1035 10.1056/NEJMoa010819
79. Gratze G., Fortin J., Labugger R., Binder A., Kotanko P., Timmermann B., Luft F. C., Hoehe M. R., Skrabal F., β -2 adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension 1999 33 6 1425 1430 2-s2.0-0033017630 (Pubitemid 29282665)
80. Hoit B. D., Suresh D. P., Craft L., Walsh R. A., Liggett S. B., β 2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. American Heart Journal 2000 139 3 537 542 2-s2.0-0033621973 (Pubitemid 30149205)
81. Leineweber K., Beta-adrenergic receptor polymorphism in human cardiovascular disease. Annals of Medicine 2004 36 supplement 1 64 69 2-s2.0-2442692712 10.1080/17431380410032544 (Pubitemid 38669926)
82. Bell C., cbell@cahs.colostate.edu Stob N. R., Seals D. R., Thermogenic responsiveness to nonspecific β -adrenergic stimulation is not related to genetic variation in codon 16 of the β 2-adrenergic receptor. American Journal of Physiology 2006 290 4 E703 E707 10.1152/ajpendo.00411.2005
83. Clement K., Vaisse C., Manning B. S. J., Basdevant A., Guy-Grand B., Ruiz J., Silver K. D., Shuldiner A. R., Froguel P., Strosberg A. D., Genetic variation in the β 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. The New England Journal of Medicine 1995 333 6 352 354 2-s2.0-0028978910 10.1056/NEJM199508103330605
84. Sakane N., Yoshida T., Umekawa T., Kogure A., Takakura Y., Kondo M., Effects of Trp64Arg mutation in the β 3-adrenergic receptor gene on weight loss, body fat distribution, glycemic control, and insulin resistance in obese type 2 diabetic patients. Diabetes Care 1997 20 12 1887 1890 2-s2.0-0030731084 (Pubitemid 27522901)
85. Umekawa T., Yoshida T., Sakane N., Kogure A., Kondo M., Honjyo H., Trp64Arg mutation of β 3-adrenoceptor gene deteriorates lipolysis induced by β 3-adrenoceptor agonist in human omental adipocytes. Diabetes 1999 48 1 117 120 2-s2.0-0032589914 10.2337/diabetes.48.1.117 (Pubitemid 29019361)
86. Endo K., Yanagi H., Hirano C., Hamaguchi H., Tsuchiya S., Tomura S., Association of Trp64Arg polymorphism of the β 3-adrenergic receptor gene and no association of Gln223Arg polymorphism of the leptin receptor gene in Japanese schoolchildren with obesity. International Journal of Obesity 2000 24 4 443 449 (Pubitemid 30198097)
87. 3-adrenergic receptor is associated with type 2 diabetes and obesity in a large Japanese sample. Diabetes Care 2001 24 9 1579 1583 2-s2.0-0035462465 (Pubitemid 33716452)
88. 2-adrenergic receptor variants and obesity, hypertension and type 2 diabetes in 7,808 white subjects. Diabetologia 2007 50 3 563 568 2-s2.0-33846786457 10.1007/s00125-006-0578-8 (Pubitemid 46215499)
89. Kurokawa N., Nakai K., Kameo S., Liu Z. M., Satoh H., Association of BMI with the β 3-adrenergic receptor gene polymorphism in Japanese: meta-analysis. Obesity Research 2001 9 12 741 745 2-s2.0-0035650476 (Pubitemid 33603888)
90. Arner P., The β 3-adrenergic receptor-a cause and cure of obesity? The New England Journal of Medicine 1995 333 6 382 383 2-s2.0-0029084089 10.1056/NEJM199508103330612
91. Hoffstedt J., Poirier O., Thörne A., Lönnqvist F., Herrmann S. M., Cambien F., Arner P., Polymorphism of the human β 3-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function. Diabetes 1999 48 1 203 205 2-s2.0-0032589901 10.2337/diabetes.48.1.203 (Pubitemid 29019374)
92. Walston J., Silver K., Bogardus C., Knowler W. C., Celi F. S., Austin S., Manning B., Strosberg A. D., Stern M. P., Raben N., Sorkin J. D., Roth J., Shuldiner A. R., Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β 3-adrenergic-receptor gene. The New England Journal of Medicine 1995 333 6 343 347 2-s2.0-0029084088 10.1056/ NEJM199508103330603
93. Ellsworth D. L., Coady S. A., Chen W., Srinivasan S. R., Boerwinkle E., Berenson G. S., berenson@mailhost.tcs.tulane.edu Interactive effects between polymorphisms in the β -adrenergic receptors and longitudinal changes in obesity. Obesity Research 2005 13 3 519 526
94. Trombetta I. C., Batalha L. T., Rondon M. U. P. B., Laterza M. C., Frazzatto E., Alves M. J. N. N., Santos A. C., Brum P. C., Barretto A. C. P., Halpern A., Villares S. M. F., Negrão C. E., Gly16+Glu27 β 2-adrenoceptor polymorphisms cause increased forearm blood flow responses to mental stress and handgrip in humans. Journal of Applied Physiology 2005 98 3 787 794 2-s2.0-20044381464 10.1152/japplphysiol.00503.2004 (Pubitemid 40283655)
95. Sandilands A., Yeo G., Brown M. J., O'Shaughnessy K. M., Functional responses of human β 1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms. Pharmacogenetics 2004 14 6 343 349 2-s2.0-3042647164 10.1097/00008571-200406000-00003 (Pubitemid 38813688)
96. Tomaszewski M., Brain N. J. R., Charchar F. J., Wang W. Y. S., Lacka B., Padmanabahn S., Clark J. S., Anderson N. H., Edwards H. V., Zukowska- Szczechowska E., Grzeszczak W., Dominiczak A. F., Essential hypertension and β 2-adrenergic receptor gene: linkage and association analysis. Hypertension 2002 40 3 286 291 2-s2.0-0036707448 10.1161/01.HYP.0000029105. 21202.FE (Pubitemid 35006712)
97. Herrmann S. M., Nicaud V., Tiret L., Evans A., Kee F., Ruidavets J. B., Arveiler D., Luc G., Morrison C., Hoehe M. R., Paul M., Cambien F., Polymorphisms of the β 2-adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies. Journal of Hypertension 2002 20 2 229 235 2-s2.0-18344419331 10.1097/00004872-200202000-00012 (Pubitemid 34913787)
98. Masuo K., Mikami H., Ogihara T., Tuck M. L., Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. American Journal of Hypertension 1997 10 1 77 83 2-s2.0-0031036701 10.1016/S0895-7061(96)00303-2 (Pubitemid 27038975)
99. Kannel W. B., McGee D. L., Diabetes and cardiovascular disease. The Framingham study. The Journal of the American Medical Association 1979 241 19 2035 2038 2-s2.0-0018764335 10.1001/jama.241.19.2035 (Pubitemid 9228506)
100. Frighi V., Stratton I., Holman R., Matthews D., Neil A., Turner R., Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. Journal of Hypertension 1993 11 3 319 325 2-s2.0-0027154921 (Pubitemid 23124939)
101. Tack G. J. J., Smits P., Willemsen J. J., Lenders J. W. M., Thien T., Lutterman J. A., Effects of insulin on vascular tone and sympathetic nervous system in NIDDM. Diabetes 1996 45 1 15 22 2-s2.0-13344249788 (Pubitemid 26010417)
102. Masuo K., Rakugi H., Ogihara T., Esler M. D., Lambert G. W., Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Current Diabetes Reviews 2010 6 2 58 67 2-s2.0-77950815768 10.2174/157339910790909396
103. Julius S., Nesbitt S., Sympathetic overactivity in hypertension a moving target. American Journal of Hypertension 1996 9 11 113s 120s 2-s2.0-0029804681
104. Mancia G., Grassi G., Giannattasio C., Seravalle G., Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999 34 4, part 2 724 728 2-s2.0-0032751208 (Pubitemid 29501288)
105. Esler M., Jennings G., Lambert G., Noradrenaline release and the pathophysiology of primary human hypertension. American Journal of Hypertension 1989 2 3, part 2 140S 146S (Pubitemid 19082354)
106. Joles J. A., Koomans H. A., Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004 43 4 699 706 2-s2.0-1642460746 10.1161/01.HYP.0000121881.77212.b1 (Pubitemid 38405571)
107. Schlaich M. P., Socratous F., Hennebry S., Eikelis N., Lambert E. A., Straznicky N., Esler M. D., Lambert G. W., Sympathetic activation in chronic renal failure. Journal of the American Society of Nephrology 2009 20 5 933 939 2-s2.0-65649109067 10.1681/ASN.2008040402
108. Bulger R. E., Burke T. J., Cronin R. E., Morphology of norepinephrine-induced acute renal failure in the dog. Anatomical Record 1986 214 4 341 347 (Pubitemid 16078825)
109. Amann K., Koch A., Hofstetter J., Gross M. L., Haas C., Orth S. R., Ehmke H., Rump L. C., Ritz E., Glomerulosclerosis and progression: effect of subantihypertensive doses of α and β blockers. Kidney International 2001 60 4 1309 1323 2-s2.0-0034787072 10.1046/j.1523-1755.2001.00936.x (Pubitemid 32962590)
110. Zoccali C., Mallamaci F., Parlongo S., Cutrupi S., Benedetto F. A., Tripepi G., Bonanno G., Rapisarda F., Fatuzzo P., Seminara G., Cateliotti A., Stancanelli B., Malatino L. S., Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002 105 11 1354 1359 2-s2.0-0037133633 10.1161/hc1102.105261 (Pubitemid 34260428)
111. Petersson M., Friberg P., Eisenhofer G., Lambert G., Rundqvist B., Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. European Heart Journal 2005 26 9 906 913 2-s2.0-18744401076 10.1093/eurheartj/ehi184 (Pubitemid 40676571)
112. Masuo K., kmasuo@baker.edu.au Katsuya T., Sugimoto K., Kawaguchi H., Rakugi H., Ogihara T., Tuck M. L., High plasma norepinephrine levels associated with β 2-adrenoceptor polymorphisms predict future renal damage in nonobese normotensive individuals. Hypertension Research 2007 30 6 503 511 10.1291/hypres.30.503 (Pubitemid 47083120)
113. Ksiazek A., Załuska W., Sympathetic overactivity in uremia. Journal of Renal Nutrition 2008 18 1 118 121 2-s2.0-37049034231 10.1053/j.jrn.2007.10.024 (Pubitemid 350251839)
114. Krum H., Schlaich M., Whitbourn R., Sobotka P. A., Sadowski J., Bartus K., Kapelak B., Walton A., Sievert H., Thambar S., Abraham W. T., Esler M., Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. The Lancet 2009 373 9671 1275 1281 2-s2.0-64049084640 10.1016/S0140-6736(09)60566-3
115. Schlaich M. P., Sobotka P. A., Krum H., Lambert E., Esler M. D., Renal sympathetic-nerve ablation for uncontrolled hypertension. The New England Journal of Medicine 2009 361 9 932 934 2-s2.0-69349085170 10.1056/NEJMc0904179